Compare Beyond Meat Inc (BYND) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Johnson & Johnson — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 2906.5× Beyond Meat Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| BYND | JNJ | |
|---|---|---|
Market Cap | $215.41M | $626.09B |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $267.24 |
52-Week Low | $0.42 | $172.78 |
Enterprise Value | $455.69M | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.4066, down 21.81% amid a 1-for-30 reverse stock split announcement. The stock is technically bearish with negative cash flow from operations, though recent quarters show mixed earnings beats. Revenue has declined from $419M in 2022 to $275M in 2025, but net income turned positive at $178M in 2025, driven by a one-time gain. Analyst sentiment is heavily skewed toward sell ratings, reflecting skepticism about the company's turnaround efforts and persistent cash burn.
The outlook remains challenging due to declining sales, high cash burn, and weak investor confidence. While valuation ratios like P/S of 0.61 appear low, the risk of further dilution or delisting outweighs potential upside. Key risks include execution missteps and competitive pressure in the plant-based food sector.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
